ORMP - オラメド・ファ―マシュ―ティカルズ (Oramed Pharmaceuticals Inc.)

ORMPのニュース

   Oral Biologics Market is Booming Worldwide with Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals  2020/11/25 06:09:30 OpenPR
Global Oral Biologics Market Report 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities,
   Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020  2020/11/12 13:40:00 PR Newswire
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific…
   Oramed Pharmaceuticals : Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients | MarketScreener  2020/09/15 12:26:04 MarketScreener
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results… | September 15, 2020
   Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients  2020/09/15 12:25:00 Benzinga
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oral Biologics Market is Booming Worldwide with Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals  2020/11/25 06:09:30 OpenPR
Global Oral Biologics Market Report 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities,
   Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020  2020/11/12 13:40:00 PR Newswire
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific…
   Oramed Pharmaceuticals : Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients | MarketScreener  2020/09/15 12:26:04 MarketScreener
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results… | September 15, 2020
   Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients  2020/09/15 12:25:00 Benzinga
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020  2020/11/12 13:40:00 PR Newswire
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific…
   Oramed Pharmaceuticals : Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients | MarketScreener  2020/09/15 12:26:04 MarketScreener
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results… | September 15, 2020
   Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients  2020/09/15 12:25:00 Benzinga
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…

calendar